EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nanomedicine Targeting Macrophage Immunometabolism in Atherosclerosis: Mechanisms and Therapeutic Prospects

Zhenyu Liu, Wenfan Yang, Na Wang, Ya Wu

Organ Medicine · 2026-03 · 3 (1) · 27-53

DOI: 10.1002/orm2.70037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Organ Medicine, online erschienen am 17.03.2026. Verfasst von Zhenyu Liu und 3 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerosis, a chronic inflammatory–metabolic disorder, remains a leading cause of cardiovascular morbidity worldwide. This review explores the emerging paradigm of nanomedicine‐based targeting of macrophage immunometabolic reprogramming as a potentially transformative strategy for atherosclerosis treatment. We emphasize innovative approaches such as stimulus–responsive nanocarriers (e.g., pH‐, reactive oxygen species‐, or enzyme‐activated systems) for spatiotemporal drug delivery and metabolic modulation within plaques, and nanoplatforms for delivering genetic regulators (e.g., small interfering RNA or microRNA) for precise manipulation of key metabolic targets, including 6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase 3 (glycolysis) and ATP‐binding cassette A1 (cholesterol efflux). Despite promising preclinical outcomes, clinical translation faces substantial challenges, including optimizing nanocarrier biocompatibility, achieving subtype‐specific targeting amid macrophage heterogeneity, and resolving scalability and standardization issues. Future advancements will require interdisciplinary collaboration integrating immunometabolism, materials science, and artificial intelligence to develop next‐generation nanotherapeutics, coupled with robust clinical validation to facilitate their translation into personalized therapies for atherosclerosis.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, Z., Yang, W., Wang, N., & Wu, Y. (2026). Nanomedicine Targeting Macrophage Immunometabolism in Atherosclerosis: Mechanisms and Therapeutic Prospects. Organ Medicine, 3(1), 27-53. https://doi.org/10.1002/orm2.70037

Vancouver

Liu Z, Yang W, Wang N, Wu Y. Nanomedicine Targeting Macrophage Immunometabolism in Atherosclerosis: Mechanisms and Therapeutic Prospects. Organ Medicine. 2026;3(1):27-53. doi:10.1002/orm2.70037

BibTeX
@article{Liu2026,
  author = {Liu, Zhenyu and Yang, Wenfan and Wang, Na and Wu, Ya},
  title = {Nanomedicine Targeting Macrophage Immunometabolism in Atherosclerosis: Mechanisms and Therapeutic Prospects},
  journal = {Organ Medicine},
  year = {2026},
  volume = {3},
  number = {1},
  pages = {27--53},
  doi = {10.1002/orm2.70037}
}
Kostenlos starten →